vs
NEOGENOMICS INC（NEO）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是NEOGENOMICS INC的1.1倍（$207.3M vs $186.7M），NEOGENOMICS INC净利率更高（-57.9% vs -62.0%，领先4.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 11.1%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 6.5%）
新基因组公司（NeoGenomics）是美国一家经CLIA认证的临床实验室企业，提供药企服务与信息服务，专注于癌症基因诊断检测，旗下检测服务涵盖细胞遗传学、荧光原位杂交（FISH）、流式细胞术、免疫组化、解剖病理学及分子遗传学等多个领域，为肿瘤相关诊断提供专业支持。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
NEO vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $186.7M | $207.3M |
| 净利润 | $-108.0M | $-128.6M |
| 毛利率 | 43.3% | — |
| 营业利润率 | — | -54.7% |
| 净利率 | -57.9% | -62.0% |
| 营收同比 | 11.1% | 25.9% |
| 净利润同比 | 42.0% | 3.5% |
| 每股收益（稀释后） | $-0.13 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $186.7M | — | ||
| Q4 25 | $190.2M | $207.3M | ||
| Q3 25 | $187.8M | $159.9M | ||
| Q2 25 | $181.3M | $166.5M | ||
| Q1 25 | $168.0M | $139.3M | ||
| Q4 24 | $172.0M | $164.6M | ||
| Q3 24 | $167.8M | $139.5M | ||
| Q2 24 | $164.5M | $147.0M |
| Q1 26 | $-108.0M | — | ||
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $-27.1M | $-180.4M | ||
| Q2 25 | $-45.1M | $-115.0M | ||
| Q1 25 | $-25.9M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $-17.7M | $-133.5M | ||
| Q2 24 | $-18.6M | $-131.6M |
| Q1 26 | 43.3% | — | ||
| Q4 25 | 43.8% | — | ||
| Q3 25 | 42.8% | — | ||
| Q2 25 | 42.6% | — | ||
| Q1 25 | 43.6% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 44.6% | — | ||
| Q2 24 | 44.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | -54.7% | ||
| Q3 25 | -14.4% | -106.9% | ||
| Q2 25 | -26.3% | -64.8% | ||
| Q1 25 | -16.6% | -102.6% | ||
| Q4 24 | -10.7% | -74.3% | ||
| Q3 24 | -12.6% | -94.6% | ||
| Q2 24 | -13.3% | -79.1% |
| Q1 26 | -57.9% | — | ||
| Q4 25 | — | -62.0% | ||
| Q3 25 | -14.4% | -112.8% | ||
| Q2 25 | -24.9% | -69.0% | ||
| Q1 25 | -15.4% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | -10.5% | -95.7% | ||
| Q2 24 | -11.3% | -89.5% |
| Q1 26 | $-0.13 | — | ||
| Q4 25 | — | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.1M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $828.8M | $-80.0M |
| 总资产 | $1.3B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | $146.1M | — | ||
| Q4 25 | $159.6M | $421.0M | ||
| Q3 25 | $164.1M | $202.5M | ||
| Q2 25 | $154.7M | $176.3M | ||
| Q1 25 | $346.2M | $127.1M | ||
| Q4 24 | $367.0M | $174.0M | ||
| Q3 24 | $362.0M | $150.6M | ||
| Q2 24 | $355.1M | $480.7M |
| Q1 26 | — | — | ||
| Q4 25 | $341.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $541.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $828.8M | — | ||
| Q4 25 | $836.6M | $-80.0M | ||
| Q3 25 | $838.3M | $9.2M | ||
| Q2 25 | $854.0M | $151.3M | ||
| Q1 25 | $888.3M | $144.2M | ||
| Q4 24 | $902.3M | $255.0M | ||
| Q3 24 | $908.2M | $346.8M | ||
| Q2 24 | $915.9M | $432.4M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.4B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.6B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.41× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.60× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | $-8.1M | — | ||
| Q4 25 | $1.3M | $-99.8M | ||
| Q3 25 | $8.9M | $-91.4M | ||
| Q2 25 | $20.3M | $-108.3M | ||
| Q1 25 | $-25.3M | $-166.5M | ||
| Q4 24 | $9.8M | $-79.3M | ||
| Q3 24 | $9.2M | $-67.0M | ||
| Q2 24 | $13.9M | $-77.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-6.5M | $-100.8M | ||
| Q3 25 | $570.0K | $-92.7M | ||
| Q2 25 | $14.0M | $-110.7M | ||
| Q1 25 | $-29.8M | $-167.8M | ||
| Q4 24 | $-1.8M | $-79.5M | ||
| Q3 24 | $-1.6M | $-68.6M | ||
| Q2 24 | $814.0K | $-79.0M |
| Q1 26 | — | — | ||
| Q4 25 | -3.4% | -48.6% | ||
| Q3 25 | 0.3% | -58.0% | ||
| Q2 25 | 7.7% | -66.5% | ||
| Q1 25 | -17.8% | -120.5% | ||
| Q4 24 | -1.0% | -48.3% | ||
| Q3 24 | -0.9% | -49.2% | ||
| Q2 24 | 0.5% | -53.7% |
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | 0.5% | ||
| Q3 25 | 4.4% | 0.8% | ||
| Q2 25 | 3.5% | 1.5% | ||
| Q1 25 | 2.7% | 1.0% | ||
| Q4 24 | 6.7% | 0.1% | ||
| Q3 24 | 6.4% | 1.2% | ||
| Q2 24 | 8.0% | 1.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NEO
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
